NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free HROW Stock Alerts $18.17 +0.21 (+1.17%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$17.84▼$18.2850-Day Range$10.00▼$18.5652-Week Range$7.60▼$22.63Volume220,423 shsAverage Volume465,270 shsMarket Capitalization$642.85 millionP/E RatioN/ADividend YieldN/APrice Target$28.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harrow alerts: Email Address Harrow MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.4% Upside$28.60 Price TargetShort InterestHealthy14.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 9 Articles This WeekInsider TradingAcquiring Shares$1.86 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.51) to $0.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.34 out of 5 starsMedical Sector274th out of 905 stocksPharmaceutical Preparations Industry127th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 3 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted14.08% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Harrow has recently decreased by 9.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 3.9 News and Social Media Coverage News SentimentHarrow has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Harrow this week, compared to 2 articles on an average week.Search Interest24 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows7 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,864,011.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.67% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.51) to $0.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -19.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -19.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About Harrow Stock (NASDAQ:HROW)Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesMay 28, 2024 | insidertrades.com3 Stocks Insiders are Buying That Should be on Your Radar (HROW)June 7 at 6:30 AM | investorplace.comThe Top 7 Growth Stocks to Buy and Hold Until 2030June 5 at 7:00 AM | businesswire.comHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension StudyJune 5 at 3:00 AM | americanbankingnews.comHarrow (NASDAQ:HROW) PT Raised to $25.00June 4, 2024 | americanbankingnews.comHarrow (NASDAQ:HROW) Price Target Increased to $25.00 by Analysts at Lake Street CapitalMay 15, 2024 | insidermonkey.comHarrow Health, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call TranscriptMay 15, 2024 | businesswire.comHarrow to Present at Two Investor Conferences in MayMay 15, 2024 | finance.yahoo.comHarrow Inc (HROW) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic AdvancesMay 15, 2024 | finance.yahoo.comHarrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo FinanceMay 15, 2024 | markets.businessinsider.comHarrow Health’s Promising Growth Trajectory and Strong Financial Outlook Reinforce Buy RatingMay 14, 2024 | seekingalpha.comHarrow, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 13, 2024 | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)May 13, 2024 | businesswire.comHarrow Announces First Quarter 2024 Financial ResultsMay 13, 2024 | businesswire.comHarrow Names Greg DiPasquale as Senior Vice President, Head of CommercialMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)May 2, 2024 | seekingalpha.comHarrow: Merits A Buy On Sales PotentialMay 2, 2024 | seekingalpha.comHarrow: The Bull Thesis Is On Track, But Short-Term Challenges LoomApril 25, 2024 | businesswire.comHarrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024April 20, 2024 | finance.yahoo.comHarrow, Inc. (HROW)April 3, 2024 | bizjournals.comMelt Pharmaceuticals raises $24 million for drug developmentApril 2, 2024 | finance.yahoo.comMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingMarch 21, 2024 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comWhy Is Harrow (HROW) Stock Up 5% Today?March 20, 2024 | seekingalpha.comHarrow, Inc. 2023 Q4 - Results - Earnings Call PresentationSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/07/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$28.60 High Stock Price Target$34.40 Low Stock Price Target$25.00 Potential Upside/Downside+57.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-22.59% Pretax Margin-21.88% Return on Equity-39.82% Return on Assets-8.13% Debt Debt-to-Equity Ratio3.06 Current Ratio3.00 Quick Ratio2.75 Sales & Book Value Annual Sales$130.19 million Price / Sales4.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book9.04Miscellaneous Outstanding Shares35,380,000Free Float30,545,000Market Cap$642.85 million OptionableOptionable Beta0.88 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEOKindred BiosciencesNASDAQ:KINLifeVantageNASDAQ:LFVNGeronNASDAQ:GERNRhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Bought 100,600 shares on 5/29/2024Ownership: 11.081%Kennedy Capital Management LLCSold 644 shares on 5/16/2024Ownership: 0.336%California State Teachers Retirement SystemSold 3,278 shares on 5/16/2024Ownership: 0.084%Bayesian Capital Management LPBought 14,002 shares on 5/16/2024Ownership: 0.040%Price T Rowe Associates Inc. MDBought 1,033 shares on 5/15/2024Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions Should I buy or sell Harrow stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow's stock price target for 2024? 3 brokers have issued 12-month price targets for Harrow's stock. Their HROW share price targets range from $25.00 to $34.40. On average, they anticipate the company's share price to reach $28.60 in the next year. This suggests a possible upside of 57.4% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2024? Harrow's stock was trading at $11.20 on January 1st, 2024. Since then, HROW shares have increased by 62.2% and is now trading at $18.17. View the best growth stocks for 2024 here. Are investors shorting Harrow? Harrow saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,980,000 shares, a decrease of 9.5% from the April 30th total of 5,500,000 shares. Based on an average daily trading volume, of 510,400 shares, the short-interest ratio is currently 9.8 days. View Harrow's Short Interest. When is Harrow's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our HROW earnings forecast. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.03. The company earned $34.59 million during the quarter, compared to analyst estimates of $34.37 million. Harrow had a negative trailing twelve-month return on equity of 39.82% and a negative net margin of 22.59%. What ETF holds Harrow's stock? Jacob Forward ETF holds 9,864 shares of HROW stock, representing 6.53% of its portfolio. What guidance has Harrow issued on next quarter's earnings? Harrow issued an update on its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $184.8 million. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). Who are Harrow's major shareholders? Harrow's stock is owned by many different institutional and retail investors. Top institutional investors include Opaleye Management Inc. (11.08%), Vanguard Group Inc. (5.17%), Wasatch Advisors LP (1.10%), Rice Hall James & Associates LLC (0.69%), Woodmont Investment Counsel LLC (0.60%) and Kennedy Capital Management LLC (0.34%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HROW) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredSecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type ...Porter & Company | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.